How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about osimertinib

Marketing authorisation indication

2.1

Osimertinib (Tagrisso, AstraZeneca) is indicated for 'the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum‑based chemoradiation therapy'.

Price

2.3

The list price of osimertinib (40 mg or 80 mg) is £5,770 per 30‑tablet pack (excluding VAT; BNF online accessed June 2025).

2.4

The company has a commercial arrangement. This makes osimertinib available to the NHS with a discount and it would have also applied to this indication if osimertinib had been recommended. The size of the discount is commercial in confidence.